The industry has made unequivocal advances, from tangible progress using artificial intelligence to robust biomarker development, permitting precise prognosis, astute stratification, and meticulous patient monitoring. Unsurprisingly, this is reflected by countless recent approvals, IND filings, and new companies emerging out of stealth-mode.

The Precision Medicine in Inflammatory Bowel Disease Summit returned for the second year, as the most comprehensive, ultra-specialized meeting and united experts to explore developments to fast-track the optimization of drug development and overcome the one-size-fits-all approach to medicine.